ResMed (RMD) Q3 2024 Earnings
ResMed reported Q3 2024 revenue of $1.2B, beat analyst consensus of $1.2B by $22.8M. Diluted EPS came in at $2.13, beat the $1.91 consensus by $0.22. ResMed reports across 3 business segments, led by Sleep and Respiratory Care Devices, Masks and Accessories, and Software as a Service (SaaS).
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about ResMed's Q3 2024 earnings report.
ResMed (RMD) reported Q3 2024 earnings on April 25, 2024 after market close.
ResMed reported revenue of $1.2B and diluted EPS of $2.13 for Q3 2024.
Revenue beat the consensus estimate of $1.2B by $22.8M. EPS beat the consensus estimate of $1.91 by $0.22.
You can read the 10-Q periodic report (0000943819-24-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.